3-Methoxyoestra-1,3,5(10),8,14-pentaen-17-ol | 1071557-46-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3-Methoxyoestra-1,3,5(10),8,14-pentaen-17-ol
• 英文别名: (13S)-3-methoxy-13-methyl-6,7,11,12,16,17-hexahydrocyclopenta[a]phenanthren-17-ol
• CAS: 1071557-46-4
• 化学式: C₁₉H₂₂O₂
• 分子量: 282.382
• InChiKey: MJWLYGQYARYJOJ-GGYWPGCISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Cortistatin analogues and syntheses and uses thereof
  申请人：President and Fellows of Harvard College

  公开号：US10273264B2

  公开（公告）日：2019-04-30

  Compounds of Formula (A′), (B′), (C′), (D′), (E′), (A″), (B″), (C″), (D″), (E″), (G1), and (G2) are useful as therapeutics for treating a wide variety of conditions in a host such as a human, e.g., including but not limited to, conditions associated with angiogenesis and/or which are mediated by CDK8 and/or CDK19 kinase activity. Also provided are methods of modulating the β-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using an effective amount of a compound of Formula (A′), (B′), (C′), (D′), (E′), (A″), (B″), (C″), (D″), (E″), (G1), or (G2).

  式(A′)、(B′)、(C′)、(D′)、(E′)、(A″)、(B″)、(C″)、(D″)、(E″)、(G1)和(G2)的化合物可作为治疗剂用于治疗宿主如人类的多种疾病，例如、包括但不限于与血管生成相关的病症和/或由 CDK8 和/或 CDK19 激酶活性介导的病症。还提供了调节β-catenin通路的方法、调节STAT1活性的方法、调节TGFβ/BMP通路的方法、调节细胞中HIF-1-α活性的方法、以及使用有效量的式(A′)、(B′)、(C′)、(D′)、(E′)、(A″)、(B″)、(C″)、(D″)、(E″)、(G1)或(G2)化合物增加 BIM 表达以诱导细胞凋亡的方法。
• CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF
  申请人：President and Fellows of Harvard College

  公开号：US20180118778A1

  公开（公告）日：2018-05-03

  Compounds of Formula (A′), (B′), (C′), (D′), (E′), (A″), (B″), (C″), (D″), (E″), (G1), and (G2) are useful as therapeutics for treating a wide variety of conditions in a host such as a human, e.g., including but not limited to, conditions associated with angiogenesis and/or which are mediated by CDK8 and/or CDK19 kinase activity. Also provided are methods of modulating the β-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1-alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using an effective amount of a compound of Formula (A′), (B′), (C′), (D′), (E′), (A″), (B″), (C″), (D″), (E″), (G1), or (G2).